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Abstract
The human microbiome can play key roles in disease, and diagnostic testing will soon have the ability to examine
these roles in the context of clinical applications. Currently, most diagnostic testing in pathology applications
focuses on a small number of disease-causing microbes and dismisses the whole microbial community that causes
or is modulated by disease. Microbiome modifications have already provided clinically relevant insights in gut
and oral diseases, such as irritable bowel disease, but there are currently limitations when clinically examining
microbiomes outside of these body sites. This is critical, as the majority of microbial samples used in pathology
originate from body sites that contain low concentrations of microbial DNA, including skin, tissue, blood, and
urine. These samples, also known as low microbial biomass samples, are difficult to examine without careful con-
sideration and precautions to mitigate contamination and biases. Here, we present the limitations when analysing
low microbial biomass samples using current protocols and techniques and highlight the advantages that micro-
biome testing can offer diagnostics in the future, if the proper precautions are implemented. Specifically, we dis-
cuss the sources of contamination and biases that may result in false assessments for these sample types. Finally,
we provide recommendations to mitigate contamination and biases from low microbial biomass samples during
diagnostic testing, which will be especially important to effectively diagnose and treat patients using microbiome
analyses.
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Introduction
Existing pathology techniques currently survey small
numbers of disease-causing microbes by applying
Koch’s postulates. Koch’s postulates explain the rela-
tionship between a single culturable microbial isolate
and a disease, but these postulates only explain a small
number of microbial related diseases [1]. The signifi-
cance of more microbially complex diseases is now
well appreciated. In most cases, human genetics and
single microbes do not explain the full disease pathol-
ogy, such as urinary tract infections [2] or periodontitis
[3]. Such diseases result from polymicrobial infections
or complex interspecies interactions that can only be
understood by looking at the microbiome – an ecosys-
tem of complex microbial communities – in conjunc-
tion with human genetics and transcriptomics [4,5].
The human microbiome consists of diverse microbial
communities (microbiota) that live on external and
internal surfaces of the human body [6], as well as the
genetic content and environment of these microbes.
Disruptions to the microbiota, through factors such as
diet, environment, and medical treatment
(i.e. antibiotics), can alter the microbiota structure and
contribute to disease [7]. It is now known that numer-
ous non-infectious diseases, including inflammatory
bowel disease [7], asthma [8], and neurological disor-
ders [9], are associated with alterations in the
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microbiome. However, current techniques used in
pathology cannot readily detect and characterise eco-
system shifts within these communities, as well as
unknown or unculturable pathogens, which can impact
the ability to accurately diagnose some diseases.
Most ongoing microbiome research is focused on
areas of the body that have high concentrations of
microbes (i.e. gut or mouth). However, most samples
used for pathological screening have fewer microbes
and are known as low microbial biomass samples.
Low microbial biomass samples can be easily over-
whelmed by contamination from background DNA
and are more prone to technical biases, such as over-
amplification during PCR [10–13]. As investigations
into low microbial biomass body sites increase, it is
vital that new protocols and techniques are applied to
minimise the effect that contamination and biases have
on these samples and that the limitations are fully
understood when developing diagnostic tools based on
the results. Here, we review the current techniques
used in diagnostic testing and discuss how microbiome
assessments can be incorporated into pathology in the
future, as many of these techniques have not yet been
successfully developed in a diagnostic setting. Lastly,
we discuss issues during analysis of low microbial bio-
mass samples in past studies, while highlighting the
sources of contamination and biases, and review tech-
niques that can be applied to minimise these con-
founding factors as microbiome tools are developed
moving forward.
Assessing and treating diseases in pathology: The
present and the future
Limitations of current diagnostic testing for single
pathogens
Current diagnostic testing is continuously improving
with technological advancements, allowing for more
accurate detection of diseases and providing informa-
tion for precise treatment options. Most current prac-
tices used to identify a microorganism during an
infection involve collecting a sample (e.g. swab,
bodily fluid, or tissue) of the infected area. The sample
is then prepared for microscopic analysis, culture, or a
PCR-based method to identify a single or small range
of pathogenic species that were previously
characterised to cause those disease symptoms [14].
However, identifying specific disease-causing
microbes can be a time-consuming process [15], dur-
ing a period when patients are potentially left
untreated or are administered treatments that are not
targeted for a specific condition, such as broad-
spectrum antibiotics [16]. In addition, this technology
cannot identify unknown pathogens or diverse mix-
tures of microbes, resulting in delays when investigat-
ing rapidly emerging, novel, or unculturable pathogens
[17,18]. Lastly, contamination from sample collection
and laboratory technicians is not adequately addressed
at present. There seems to be no national or interna-
tional standard that specifically standardises sample
collection, with the exception of gloves to be worn to
protect the technician. This dismissal of protecting the
integrity of the sample could lead to the inadvertent
introduction of additional microbes into the sample,
which can modify or bias results, and could ultimately
result in incorrect diagnoses and treatment of patients
[18]. New approaches based on sensitive, high-
throughput techniques that investigate unknown
microbes, or the microbial community as a whole, are
required to mitigate some of these issues and better
identify disease sources and complications.
Benefits of microbiome analysis for pathology
Current research efforts assess changes to the micro-
biome to understand disease pathologies on a case-by-
case basis. Approaches used for microbiome analysis
can assist in characterising both communicable (infec-
tious) and non-communicable (non-infectious) diseases,
with non-communicable conditions being more preva-
lent in high-income countries [19]. Microbiome analy-
sis provides clinicians with the ability to practice
precision medicine, especially in unique or unsolved
cases, as it will enable the identification of specific
unknown pathogen(s) and the ability to monitor the
microbiota and microbiome through time, in relation-
ship to disease status and treatment [4,20,21]. A cur-
rent set of procedures to explore microbiomes in
diagnostic testing could be: sample collection from the
affected area; nucleic acid extraction; sequencing
library preparation; sequencing using high-throughput
sequencing (HTS) approaches; and finally, reconstruc-
tion of the microbiota and/or their functions using
high-throughput computing resources [22]. Several
types of HTS can be employed [23], including
amplicon based sequencing (targeting one ‘fingerprint’
or ‘barcode’ gene to identify the microbiota present,
such as the gene encoding 16S ribosomal RNA) [22];
shotgun metagenomic sequencing (assessing a random
sampling of DNA from the biological sample to recon-
struct microbial genomes and functions of known,
new, or under characterised species/strains in the
microbiome) [24]; and metatranscriptomics (examining
the actively transcribed genes using RNA based
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sequencing approaches) [25]. These approaches can
aid in the identification, function, and activity levels of
known and novel species/strains that contribute to
infectious diseases [4,26,27], which is important for
diagnosis and treatment, but also critical for the down-
stream development of new rapid and cost effective
techniques to readily detect these pathogens. Lastly,
understanding the functions of the microbiota and how
these functions are utilised is also essential to under-
stand the underpinning mechanisms of disease, within
both infectious and non-infectious conditions. The
human microbiome typically contributes over 3 million
genes in every single human, which is approximately
150 times more genes than the human genome [28].
This volume of information is not routinely assessed
in current diagnostic testing and could inform more
effective treatment strategies or identify unknown
infection dynamics. Below, we discuss in detail how
microbiome testing can provide additional information
when diagnosing communicable and non-
communicable diseases in the future.
1. Identifying infectious disease from new or unknown
pathogens
While the most common approach to diagnose an
infectious disease is to test for a single pathogen, this
approach does not explore unknown or unidentifiable
pathogens. Metagenomics analysis can be used to
reconstruct the genomes of novel or unknown patho-
gens by comparison to a distantly related species or
strain, to assemble genomes of unknown species from a
sample using de novo approaches, to reconstruct geno-
mic information, or to quantify levels of a taxon that is
present in one location but absent or lower in another,
perhaps providing information about an opportunistic
pathogen. For example, in one report, a patient suffered
with chronic meningoencephalitis for 3 years with no
known disease aetiology using standard pathology tests
[4]. An assessment of the microbiome (metagenomics)
revealed that the Cache Valley virus (not known to
cause meningoencephalitis) was responsible for the dis-
ease [4]. In concert with metagenomics analysis, host
transcriptomics can also be used to identify if a disease
is caused by an infection [4,29] by examining the active
transcription of immune genes activated during infec-
tion. Certain host genes are transcribed when fighting
an infectious disease, and these transcripts, or their
absence, can be detected using current transcriptomic
approaches, providing additional clues to the type of
infection [29]. Quantifying the level of these particular
transcripts can also distinguish between an infectious
and non-infectious disease [30,31].
2. Co-infections or diverse poly-microbial infections
Diagnostic testing is typically limited to one poten-
tial pathogen per test; however, several diseases can
manifest as co-infections or poly-microbial infections,
where multiple microorganisms contribute to the dis-
ease. Poly-microbial infections, such as those observed
in the urinary and respiratory tracts, are often difficult
to treat due to the interactions between different
microbes, so understanding the mechanisms that
underpin these infections could improve treatment
strategies [32,33]. Amplicon or metagenomic analysis
can be applied to identify numerous pathogens simul-
taneously or, potentially, assess levels of opportunistic
pathogens, if a healthy sample has been taken
previously.
3. Function(s) of disease-causing pathogen(s)
Assessing specific pathogen functions is essential to
identify the correct treatment option(s), especially in
cases where the first line of treatment is ineffective.
This is typically done by screening a cultured pathogen
against different types of antimicrobials. However, the
resistance for these antimicrobials is encoded in the
genome of each microbe, which contains specific genes
for individualised functions. For example, some patho-
gens carry antimicrobial resistance genes that can pro-
vide broad spectrum or very specific antibiotic
resistance [34]. Metagenomic sequencing could identify
which (if any) antimicrobial resistance genes a microbe
has and provide information to advise which antibiotic
would be the most specific and effective [35]. In addi-
tion, metatranscriptomics – examination of the RNA in
the microbiome – could provide key information on the
microbes that are actively playing a role in drug metab-
olism [36] or antibiotic resistance [37]. This information
could then be used for better and more targeted treat-
ment, which is especially critical in the light of rising
antibiotic resistance.
4. Microbiome functions for non-infectious diseases
Critically, microbiome assessment may prove to be
most useful during the diagnosis and treatment of non-
infectious diseases. Autoimmune, allergic, and
inflammatory disease are on the rise in industrialised
countries [38] and, in many cases, their primary causes
remain unclear [39–41]. For example, inflammatory
bowel disease has recently been linked to disruptions in
the gut microbiota, and there is research underway to
determine whether faecal microbiota transplants can be
an effective treatment [41]. Other microbiome trans-
plants have also been recently suggested, opening the
door for different types of microbiome transplantation.
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An amplicon or metagenomics-based approach could
be utilised to assess the donor’s or patient’s microbiota
or microbiome and identify which specific transplant
donor might be best, which microbial functions are
missing from the patient’s gut, or which probiotic strat-
egies may be the most useful [41]. Overall,
characterising and assessing the microbiome can be
another tool to help identify non-infectious disease cau-
ses or complications and inform more specific and
effective treatments.
Implementing microbiome analysis in pathology:
Challenges of working with low-biomass samples
While there are many advantages to investigating the
microbiome using HTS, the widespread implementa-
tion of such technologies in a medical context is still
limited by certain factors. Clinicians, pathologists, and
bioinformaticians require training to properly collect,
process, analyse, and interpret microbiome samples,
and minimum standards for laboratory analysis and
reporting are needed to ensure robust diagnosis and
treatment. In some cases (e.g. non-infectious diseases),
the microbial communities and functions linked to dis-
ease are still being described; thus, only hypotheses
related to causality and function of non-infectious dis-
eases are described [42,43]. The bioinformatics and
sequencing technologies needed to completely
describe non-infectious diseases are not adequate at
present; therefore, more research still needs to be
undertaken before the microbiome can be analysed
routinely in diagnostics [42,43]. Several issues for
implementing reliable microbiome analysis in diagnos-
tic testing are already known and need to be addressed
in the diagnostics field as microbiome testing is devel-
oped, implemented, and employed. This is largely due
to the fact that many of the samples commonly
screened in diagnostic testing contain a low microbial
biomass.
There are numerous areas of the body that are now
considered to be of low microbial biomass but were
originally thought to be sterile. For example, research
has shown that microbes colonise and perform critical
functions within the lungs, albeit at low concentrations
[44]. Other examples of low microbial biomass body
sites include skin [45], blood [46], urine [47] and tis-
sue [48] – all of which are typical samples collected
for diagnostic tests. These samples typically have
small numbers of microbial cells (100–10000 cells/
mL) [49,50] and are more difficult to examine than
those of high microbial biomass. Even in widespread
microbiome research today, common microbiome pro-
tocols [51–53] are not optimised for low microbial
biomass samples. Recent research has provided
improvements in low biomass laboratory and analysis
protocols [54,55], but there is still room for further
improvement.
The most significant issue in examining low
biomass samples is contaminating, or exogenous,
DNA (i.e. DNA from sources other than the sample of
interest), which is unintentionally introduced during
collection and processing of biological samples
[10,13,48,56]. Contaminating DNA originates from
numerous sources, including cells or small fragments
of DNA from the same environment, sampling equip-
ment, laboratory reagents and equipment, technicians,
and so on [10,12,13]. Although sterilisation lyses and
kills microbial cells, their DNA can be broken up into
smaller fragments, which can still be extracted and
amplified by PCR. Unsurprisingly, HTS is more sensi-
tive than traditional culture methods in detecting con-
tamination, and if no controls are used to identify
contamination, the results may be confounded [57].
Using these HTS approaches, contamination has
driven spurious conclusions and drastically altered
several reported biological discoveries in the literature
[56,58,59]. Especially in low microbial biomass sam-
ples, contamination and bias from contaminants has
already had severe impacts on the fidelity of reported
results [12]. As the application of microbiome research
shifts towards clinical use, contamination needs to be
monitored and accounted for to prevent patient
misdiagnoses.
Lessons from past low biomass microbiome studies
Despite the potential benefits, some researchers work-
ing with low microbial biomass samples do not use
the necessary precautions to control or limit contami-
nation. Initial studies of the gut microbiome (a source
of high microbial biomass) were less prone to contam-
ination, as contaminating DNA was negligible com-
pared to the endogenous microbial DNA (DNA
belonging to the sample of interest) present in the sam-
ple, and thus downstream analyses were not severely
impacted [60]. Researchers then followed similar pro-
tocols to examine low microbial biomass samples,
including placental tissue [58], nipple aspirate [61],
and tumours [62,63], overlooking the possible nega-
tive impacts of contamination. This resulted in gener-
ating data from low microbial biomass samples that
were overwhelmed by the amount of exogenous DNA
relative to the endogenous DNA and consequently,
contamination was falsely reported as a true result in
some studies [56,58,59]. These past errors are lessons
for the future, but we need to ensure they are not
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repeated, especially when applying microbiome tech-
niques in diagnostic testing.
Lack of controls in microbiome analysis of medical
samples has already caused issues within the field. For
example, initial investigations into the placenta micro-
biome sought to answer many questions about infant
development and preterm birth during pregnancy [58].
However, an initial study failed to use the necessary
precautions to monitor and minimise contamination.
Non-template controls were introduced during the
extractions, but only a subset were sequenced.
Sequences found in the negative controls were not crit-
ically compared to those from the biological samples.
Additionally, no environmental controls were collected
or analysed, preventing the detection of environmental
contaminants (e.g. microbes in the air, from the techni-
cian, or on sterile dissection equipment). Lastly, the
limit of detection was not established, preventing the
researchers’ ability to determine if a reliable signal
could be detected. Contaminant microbial species
could therefore not be correctly identified or assessed
within the placenta samples to determine if the micro-
bial signature from the placenta was truly endogenous.
In 2016, Lauder et al [56] replicated the study of the
placenta microbiome and found that the microbial pla-
centa profiles resembled those of extraction blank con-
trol (EBC) samples and air samples, suggesting that
the placenta was likely sterile and did not contain a
diverse microbial signal. Since then, many other well-
controlled studies have further supported the lack of a
placenta microbiome [59,64–67]. These studies high-
light the importance of having robust protocols and
controls to avoid spurious conclusions.
Sources of contamination and biases in low
microbial biomass samples
To better control for contamination and biases, a solid
understanding of when and how these factors arise is
needed. While contaminating DNA and biases can be
introduced at any stage in the sample preparation and
analysis process, three predominant sources originate
from sampling procedures and the laboratory: (1) doc-
tors, nurses, technicians, and so on; (2) environments;
and (3) reagents and equipment (Figure 1). More
recently, there has been an increased awareness of
contamination and biases introduced into low micro-
bial biomass samples, but widespread inclusion and
analysis of controls still needs to be broadly
implemented and reported [12,57,68]. Below, we
review the current information on sources of contami-
nation and biases and provide recommendations for
reducing these confounding factors when using micro-
biome assessments in diagnostic testing.
Sample collectors and technicians in the clinic and the
laboratory
Professionals who collect and process samples may
introduce their own microbial DNA into a sample
(Figure 1), which is especially problematic when mul-
tiple individuals are collecting and processing samples
for the same study or test. Most clinical protocols do
not address microbial DNA contamination introduced
from sample collectors and laboratory technicians,
leading to the possibility that signals from individuals
may override the signal from the biological sample if
precautions and procedures are not put in place. Even
the best trained sample collectors and laboratory tech-
nicians will introduce contamination into the samples;
this is not an error on the part of the individual but
now an appreciated signal within microbiome research.
For example, sample collectors generally wear gloves
and occasionally face masks to protect their health;
however, DNA can be shed from unclean gloves, a
mask, a lab coat, or the collector’s unexposed skin
[69] – all sources can now be detected using new HTS
methods. To decrease the strength of these signals, all
sample collectors and laboratory technicians should
wear gloves, face masks, lab coats, and other appropri-
ate clothing to prevent contamination from the techni-
cian [12]. This problem is also not mitigated by the
use of robotics, rather than human technicians. Auto-
mated robots produce more well-to-well contamination
(cross-contamination) across samples [70], which leads
to specific batch and robot contamination. Addition-
ally, bias can be introduced into samples of low micro-
bial biomass through the technique applied by
multiple sample collectors. Simpkins et al [71] showed
that there was a significant difference in microbial spe-
cies collected between technicians of varied experience
(e.g. how hard a technician, doctor, or nurse presses
down on a skin swab to collect a sample). Future
research needs to fully characterise the contamination
and bias introduced from sample collectors and labora-
tory technicians and understand how this can influence
or alter microbial signatures in low microbial biomass
samples.
The sampling and laboratory environments
Low microbial biomass samples are also influenced by
the environment where they were collected (Figure 1)
[60]. Microbial profiles in different built and outdoor
environments are unique, and even different laborato-
ries with similar technicians and purposes have unique
profiles [10,13]. Additionally, the same lab can have
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different contaminant profiles that change according to
the season, year, or technician [13]. For example,
indoor environments, such as hospitals, resemble a
microbial profile similar to that of the inhabiting
individual(s) [72,73]. Despite this, the exact mecha-
nisms that result in environmental contamination in
low biomass samples are poorly understood. It is
likely that the majority of microbes in a sampling
environment exist in the air, in bioaerosols or on
surfaces.
Reagents and equipment from sampling and laboratory
processes
Low microbial biomass samples are highly susceptible
to contaminating DNA present in reagents and equip-
ment used for sample collection, DNA extractions, and
library preparation (Figure 1). It is well recognised that
reagents and equipment, including ‘sterile’ water, con-
tain microbial DNA [13,48,74,75]. Salter et al [10]
demonstrated that different extraction kits showed a
different amount and composition of microbial DNA,
and even the ‘cleanest’ kits contain reliable DNA sig-
natures. This becomes problematic for low microbial
biomass samples as the contaminating microbes can
overwhelm the signal from endogenous DNA content
[76,77]. During amplification, the exogenous DNA
becomes preferentially amplified, lowering the chance
of observing the true microbial signal. Varying con-
centrations of input DNA can also increase the number
of artefacts during DNA amplification, which has a
significant impact on low microbial biomass samples.
Chafee et al [11] showed that input DNA concentra-
tion biases low microbial biomass samples by increas-
ing duplication levels, favouring AT-rich sequences,
and overall biasing population levels. Generally, low
microbial biomass samples have low DNA input levels
for amplification reactions, which results in over-
amplification of the template DNA with high levels of
duplication [11,78]. This can significantly bias results,
suggesting that a single species or genus, perhaps even
a contaminant species, is more dominant in the sample
than it truly is. Consequently, these factors cause sig-
nificant issues when reconstructing microbial commu-
nities for diagnostic purposes, especially when
attempting to identify and quantify the microbes
present.
Figure 1. Microbial DNA from sample collectors and laboratory technicians, the environment, and reagents and equipment can contami-
nate pathological samples, which can distort the microbial profile of the sample.
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Recommendations to avoid potential
contamination and biases
Below, we discuss the current recommendations to avoid
potential contamination and biases when attempting to
introduce microbiome analysis into diagnostic testing.
For a quick reference guide, the RIDE checklist is also
available as minimum standards for low microbial bio-
mass samples [12].
1. Include controls from the sampling and laboratory
environments, equipment, and reagents
To detect environmental microbes, air samples of the
collection room should be gathered. Additional controls
should include swabs of the hospital room (e.g. seats,
walls, benches) before collection of biological samples.
During laboratory processes, EBCs (controls that are
run in parallel to the samples during the extraction, but
do not include sample DNA) and no-template amplifi-
cation controls (NTCs; amplification reactions without
any extracted DNA) should be included with every
extraction or amplification batch, respectively, to moni-
tor DNA incorporated into the sample via laboratory
reagents. Additional controls to monitor any tool, sub-
stance, or individual that comes in contact with the
samples may also be required for specific cases. It
should be noted that additional amplification or strate-
gies (e.g. the introduction of carrier DNA) [79] may be
required to detect contaminating DNA and should be
performed if necessary. Additionally, extraction
methods that are known to contain fewer contaminants
and are optimised for low microbial biomass samples
(e.g. Mo Bio PowerMag with a ClearMag bead [54])
should be used. Contaminating DNA simply cannot be
avoided and needs to be monitored to ensure it is not
driving the signals present in the collected samples.
2. Minimise the amount of microbial and human con-
tamination being introduced into samples
Currently, there are no established protocols to mini-
mise the introduction of microbial and human DNA into
low microbial biomass samples in a clinical setting.
However, other fields have methods that could be
adopted or modified here, including ancient DNA proto-
cols or those utilised in levels of high biosecurity
[12,13]. Generally, introducing contaminating microbial
DNA could be decreased by wearing clothing that
covers exposed skin, such as wearing face masks and
gloves. This is similar to the techniques used in ultra-
clean labs [12], where technicians are required to wear
full disposable body suits, shoe covers, face masks, a
plastic visor, and multiple pairs of gloves to minimise
the introduction of human and bacterial DNA. Human
DNA, which can overwhelm microbial DNA of many
low microbial biomass samples, can also be depleted
using methods such as Benzonase [33]. Additionally,
DNA in reagents and on equipment can be minimised
by irradiating reagents with ultraviolet radiation [80]. As
microbial DNA is ubiquitous, these strategies can aid in
reducing the contaminating DNA profile relative to the
biological one, but it is critical to understand that current
research supports the idea that it cannot be completely
eliminated and should be monitored for the best results.
3. Consistency and randomisation
Inconsistency in sample collection (e.g. differences
in pressure/duration when swabbing skin) can intro-
duce biases. To minimise these biases, the best prac-
tice is to reduce the number of sample collectors.
However, this is not possible at some diagnostic test-
ing sites, so the collection and processing of samples
should be randomised between sample collectors and
laboratory technicians to minimise any possible biases.
Alternatively, additional controls may be needed to
account for this bias. Furthermore, standardised training
and explicit sampling and processing protocols should
be implemented to ensure that samples are collected
and processed as similarly as possible. In the labora-
tory, positive controls with non-biological DNA frag-
ments (i.e. mock communities) can be utilised to
ensure that technician bias during processing is limited
and technician-specific contamination can be more
readily detected [12]; however, the user must be care-
ful that these positive controls are handled with con-
sideration to their microbial biomass level. For
example, it would be ill advised to add DNA from a
positive, high biomass control first before processing
low biomass samples in the same batch.
4. Use quantitative laboratory methods
In the past, the successful acquisition of DNA from
a sample was determined by the presence or absence
of bands on a gel. However, this technique is not sen-
sitive to the level of DNA present in many control
samples [54]. Quantitative methods, such as fluores-
cent probes (e.g. PicoGreen) or quantitative PCR,
should instead be utilised to determine the total DNA
present in both samples and controls [54,56]. This pro-
cess verifies that the biological sample has more DNA
than the controls. It is also recommended that low
input samples should be sequenced at a higher depth
to capture a sufficient number of unique
sequences [11]. Further research is still needed to
examine how low copy number biases can be best
avoided in low biomass research.
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5. Incorporating bioinformatics approaches to assess
or remove contamination
Recently, several bioinformatic methods have been
developed to track and remove contaminating DNA that
influences low microbial biomass samples. First, the limit
of detection can be applied using positive and negative
controls [54], as described above. Additionally, individ-
ual contaminating species can be tracked from their
source (i.e. environmental controls, reagents, equipment,
EBCs, NTCs, etc.) using their exact sequence [81] and
then can be subsequently removed or identified using
publicly available programs, such as SourceTracker [82]
and Decontam [64]. While programs can be used to
remove or track contaminants, the procedures do not mit-
igate the requirement to monitor and examine contami-
nants during sample collection and laboratory processes.
Conclusion
In the near future, the microbiome will become an impor-
tant asset for diagnostics and treating human diseases.
However, most pathology samples contain low numbers
of microbial cells, which makes them difficult to extract,
amplify, and analyse in a microbiome context. These low
microbial biomass samples are more prone to contamina-
tion and biases from the sample collectors and laboratory
technicians, environment, reagents, and equipment. To
avoid misdiagnoses and incorrect treatments, clear proce-
dures and guidelines are needed for pathologists and clini-
cians to mitigate contamination and biases. Several
groups, such as ancient DNA and forensic researchers,
have developed similar guidelines and protocols for ana-
lyses done in their field [80,83,84]. Proper controls, meth-
odological precautions, and appropriate analytical
strategies will allow the benefits of microbiome analysis
to be appreciated for diagnostic testing in the future.
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